Invent Farma / neuraxpharm Group announces the acquisition of FB Health in Italy
First acquisition made by Invent Farma / neuraxpharm following the creation of the Group by funds advised by Apax Partners in August 2016
Barcelona, Spain and Düsseldorf, Germany, 22nd June 2017 / Sciad Newswire / The Invent Farma / neuraxpharm Group (the Group), a leading speciality generics company focussed on CNS, today announced the acquisition of FB Health S.p.A. (FB Health), an Italy-based speciality pharma company focused on neurology and psychiatry.
Located in Ascoli Piceno, Italy, FB Health is devoted to the research, development and commercialization of innovative nutraceuticals and pharmaceuticals for the prevention and treatment of diseases in the psychiatric, neurologic and geriatric field.
FB Health was founded by Dr. Francesco Bellini, a pioneer in antiviral and Alzheimer’s drug development.
FB Health will be the newest member of the Group, which was acquired by funds advised by Apax Partners, a leading private equity firm, in August 2016. This marks the entrance of the group into its fourth direct geography after Germany, Spain and Poland.
“We are delighted to welcome the entire FB Health team into our Group and are looking forward to supporting its development by adding more CNS products from the sister companies to the existing business in Italy. With this acquisition and via future ones to come, we continue to move forward with our goal of becoming the Pan-European leader in the treatment of CNS diseases”, said Stephan Walz, Chief Executive Officer of the Invent Farma / neuraxpharm Group.
Commenting on the transaction, Dr. Francesco Bellini, Chairman of FB Health: “I am very proud of FB Health’s achievements in Italy during the past years. I want to thank management and employees for their dedication and expertise and wish them continued success as part of the Invent/Neuraxpharm family.”
Marco Marchetti, CEO of FB Health, said: “We thank our previous shareholders for their steady support during all these years. We are now happy and excited to become part of the Invent Farma / neuraxpharm family, a Group in line with our strategy in addressing unmet clinical need in the CNS field, and we are delighted to contribute to the acceleration of the consolidation of the Group in this segment.”
This is the first acquisition of Invent Farma / neuraxpharm following the creation of the Group by funds advised by Apax Partners in August 2016.
Closing of the transaction is subject to customary closing conditions and is expected to occur shortly. Terms of the transaction were not disclosed.
For further information, contact:
Corporate Communication Responsible
Tel. +34 93 475 96 00
INVENT FARMA HOLDING SPAIN S.L.
Avda. Barcelona, 69
08970 Sant Joan DespÃ (Barcelona) Spain
Notes for Editors
About Invent Farma / neuraxpharm Group
Created in August 2016, following the acquisition by funds advised by Apax Partners, the Group Invent Farma / neuraxpharm is a leader in generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS). The Group is the combination of the Barcelona-based Invent Farma with Düsseldorf-based neuraxpharm. Invent Farma has 50 years’ experience in the development, manufacturing and marketing of pharmaceutical products, while neuraxpharm is a leading CNS brand that has earned the trust of specialist doctors, pharmacists and patients in over three decades.
The Group markets, through Qualigen and neuraxpharm, generics drugs from a combined portfolio of predominantly differentiated products mainly in the CNS field. In addition, the Group owns and operates two manufacturing plants in Spain: one of the plants to produce hard-to-make active pharmaceutical ingredients (APIs) with a unique expertise in the respiratory area (Inke), and the other one to produce finished dosage forms (FDFs) across multiple therapeutic areas (Lesvi).
For more information, contact:
About FB Health (www.fb-health.com)
FB Health is an Italy-based speciality pharma company founded in 2010 focused on the research, development and commercialization of innovative nutraceuticals and pharmaceuticals in Italy for the prevention and treatment of pathologies affecting elderly people, with a particular focus towards Neurology, Geriatrics and Psychiatry
21.06.2017 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.